Valencia biotechnology company MannKind Corp. thought it had encouraging news about its experimental insulin inhaler on Tuesday. But Wall Street wasn’t buying it.
For months, skeptical traders have expressed concern that the diabetes drug, if approved by the Food and Drug Administration, might end up with an FDA cancer advisory. Fears that the inhaler would never [...]

Continue reading...